Suppr超能文献

利福平用于外科治疗的葡萄球菌感染性心内膜炎:一项倾向评分调整队列研究。

Rifampin for Surgically Treated Staphylococcal Infective Endocarditis: A Propensity Score-Adjusted Cohort Study.

作者信息

Shrestha Nabin K, Shah Shailee Y, Wang Hannah, Hussain Syed T, Pettersson Gosta B, Nowacki Amy S, Gordon Steven M

机构信息

Department of Infectious Disease, Cleveland Clinic, Cleveland, Ohio.

Department of Infectious Disease, Cleveland Clinic, Cleveland, Ohio.

出版信息

Ann Thorac Surg. 2016 Jun;101(6):2243-50. doi: 10.1016/j.athoracsur.2015.11.015. Epub 2016 Feb 10.

Abstract

BACKGROUND

Rifampin is recommended as adjunctive treatment for staphylococcal prosthetic valve endocarditis (PVE). It is unclear whether this should hold for surgically treated patients. The purpose of this study was to examine whether adjunctive rifampin treatment in addition to cell wall active antimicrobial agents in patients with surgically treated staphylococcal infective endocarditis (IE) results in better outcomes.

METHODS

Patients operated on for staphylococcal IE from April 1, 2008, to July 1, 2014, were identified from our institution's IE registry. Rifampin treatment was defined as 3 or more days of rifampin postoperatively. Cox proportional hazards regression was used to compare a composite outcome of death or reoperation for IE relapse, between patients treated and not treated with rifampin, adjusted for propensity to be treated with rifampin, methicillin resistance, all-purpose refined diagnosis related group (APR-DRG) severity score, and APR-DRG mortality risk.

RESULTS

In all, 273 patients were identified. The mean age was 56 years, 66% were male, 50% had PVE, 60% had S. aureus or S. lugdunensis infection, 89% had left side involvement, and 57% had invasive disease. Fifty-one (27%) received 3 or more days of rifampin postoperatively. Ninety-two patients died or underwent reoperation for IE relapse at a median of 205 days (interquartile range 56 to 718 days). In a multivariable model, patients treated with rifampin had a similar hazard of death or reoperation for IE relapse as those not treated (hazard ratio 0.76, 95% confidence interval 0.44 to 1.32, p value 0.34). The results were robust to varying definitions of rifampin treatment.

CONCLUSIONS

Among patients with surgically treated staphylococcal IE there was insufficient evidence to claim a reoperation-free survival benefit from treatment with rifampin. Rifampin should not be used as adjunctive therapy for staphylococcal IE in patients who have undergone surgical procedures for its treatment.

摘要

背景

利福平被推荐作为葡萄球菌人工瓣膜心内膜炎(PVE)的辅助治疗药物。对于接受手术治疗的患者,是否也应如此并不明确。本研究的目的是探讨在接受手术治疗的葡萄球菌感染性心内膜炎(IE)患者中,除细胞壁活性抗菌药物外,加用利福平辅助治疗是否能带来更好的治疗效果。

方法

从我们机构的心内膜炎登记处确定2008年4月1日至2014年7月1日期间接受葡萄球菌性IE手术的患者。利福平治疗定义为术后使用利福平3天或更长时间。采用Cox比例风险回归分析,比较接受和未接受利福平治疗的患者在因IE复发死亡或再次手术的复合结局方面的差异,并根据接受利福平治疗的倾向、耐甲氧西林情况、通用精细诊断相关组(APR-DRG)严重程度评分以及APR-DRG死亡风险进行调整。

结果

共确定了273例患者。平均年龄为56岁,66%为男性,50%患有PVE,60%感染金黄色葡萄球菌或路邓葡萄球菌,89%累及左侧,57%患有侵袭性疾病。51例(占27%)术后接受了3天或更长时间的利福平治疗。92例患者在中位时间205天(四分位间距56至718天)时死亡或因IE复发接受再次手术。在多变量模型中,接受利福平治疗的患者因IE复发死亡或再次手术的风险与未接受治疗的患者相似(风险比0.76,95%置信区间为从0.44至1.32,p值为0.34)。该结果对于利福平治疗的不同定义具有稳健性。

结论

在接受手术治疗的葡萄球菌性IE患者中,没有足够的证据表明利福平治疗能带来无再次手术生存获益。对于已接受手术治疗葡萄球菌性IE的患者,利福平不应作为辅助治疗药物使用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验